The WOMAN trial is a large pragmatic randomised double-blind, placebo controlled trial to
quantify the effects of the early administration of tranexamic acid on death, hysterectomy
and other relevant outcomes. 20,000 adult women, after delivery who have clinically diagnosed
postpartum haemorrhage, are eligible if the responsible doctor is for any reason
substantially uncertain whether or not to use an antifibrinolytic agent. Additionally, TWO
nested studies will be conducted in a subset of women trial participants. The first nested
study (ETAC) aims to evaluate the effect of tranexamic acid (TXA) on markers of coagulation
in 400 women randomised to the WOMAN trial. The second nested study (ETAPLAT) aims to
evaluate the haemostatic effect and antithrombotic effect of TXA in 128 women randomised to
the WOMAN trial.